Overview

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Status:
Completed

Trial end date:
2018-07-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Phase:

N/A

Details

Lead Sponsor:

Mitchell Grayson

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Montelukast